Abstract: A biosensor includes a multiplexed array of electrolyte-gated functionalized field effect transistors (FET). Walls fluidically separate each of the FETs from one another provide wells corresponding to each channel of the FETS. A perimeter wall on the upper surface of the multiplex array surrounding the separating walls and traversing the surface of all FETS in the multiplexed array. The perimeter forms a fluidically tight well traversing multiple ones of the FETs. Each of the FETs includes monolayer of a two dimensional material, such as graphene, as a conducting channel, wherein each conducting channel functionalized according to a predetermined agent.

Abstract: Transferring graphene pieces onto a substrate, by the following steps: a) selecting a substrate comprising a plurality of placeholders for the graphene pieces; b) disposing and aligning the substrate on a substrate holder in a chamber; c) selecting a transfer layer having openings as placeholders for the graphene pieces; d) disposing and aligning the transfer layer on the substrate holder over the substrate so that the openings of the transfer layer are aligned over the placeholders on the substrate; e) adding liquid to the chamber to above the transfer layer, and raising the transfer layer on the liquid column; f) introducing graphene pieces onto the liquid film in the openings of the transfer layer; and g) reducing the distance between the substrate and the graphene pieces until the graphene pieces are disposed on the placeholders of the substrate. A substrate and a device for carrying out the method.

Abstract: This invention is in the area of improved therapeutic combinations for and methods of treating selected cancers using selected pyrimidine compounds having pan-TAM or Mer/Axl dual receptor tyrosine kinase inhibitory activity in combination with immune checkpoint inhibitors. In one aspect, an improved treatment for select cancers is disclosed using selected pyrimidine compounds described herein in combination with an immune checkpoint inhibitor, for example, a cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitor, a programmed cell death protein 1 (PD1) inhibitor, or a programmed death-ligand 1 (PDL-1) inhibitor, or combination thereof.

Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Abstract: Transferring graphene pieces onto a substrate, by the following steps: a) selecting a substrate comprising a plurality of placeholders for the graphene pieces; b) disposing and aligning the substrate on a substrate holder in a chamber; c) selecting a transfer layer having openings as placeholders for the graphene pieces; d) disposing and aligning the transfer layer on the substrate holder over the substrate so that the openings of the transfer layer are aligned over the placeholders on the substrate; e) adding liquid to the chamber to above the transfer layer, and raising the transfer layer on the liquid column; introducing graphene pieces onto the liquid film in the openings of the transfer layer; and g) reducing the distance between the substrate and the graphene pieces until the graphene pieces are disposed on the placeholders of the substrate. A substrate and a device for carrying out the method.

Abstract: This invention is in the area of improved therapeutic combinations for and methods of treating selected cancers using selected pyrimidine compounds having pan-TAM or Mer/Axl dual receptor tyrosine kinase inhibitory activity in combination with immune checkpoint inhibitors. In one aspect, an improved treatment for select cancers is disclosed using selected pyrimidine compounds described herein in combination with an immune checkpoint inhibitor, for example, a cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitor, a programmed cell death protein 1 (PD1) inhibitor, or a programmed death-ligand 1 (PDL-1) inhibitor, or combination thereof.

Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Abstract: Compounds of Formula I or II: are described, along with pharmaceutical compositions containing the same and methods of using such compounds for the treatment of cancer.

Abstract: Compound of Formula I: are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.

Abstract: Described are compounds of Formula I or Formula II: wherein: ring A is a 5- or 6-membered heteroaryl group; dashed lines are optional double bonds; X is N or O; Y is a carbon atom or an S or N heteroatom in ring A in any suitable location; and substituents are as given herein. Compositions containing the same and methods of using the same in treating cancers such as acute lymphoblastic leukemia are also described.

Abstract: Compounds of Formula I are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof.

Abstract: Compound of Formula I: are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.

Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.

Abstract: Compound of Formula (I): are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.

Abstract: The ectopic expression of Mer receptor tyrosine kinase (Mer) has been identified as a tumor cell survival gene product in Acute Lymphoblastic Leukemia (ALL) cells and a potential cause of ALL chemoresistance. Hence, we investigated whether the development of small molecule Mer inhibitors was possible. A first aspect of the present invention is a compound (sometimes referred to as an “active compound” herein) of Formula I, IA, or IB.

Abstract: Compounds of Formula I or II: are described, along with pharmaceutical compositions containing the same and methods of using such compounds for the treatment of cancer.

Abstract: The present invention includes pyrimidine compounds that selectively inhibit Mer tyrosine kinase (MerTK) activity and/or Tyro3 tyrosine kinase activity, and use of these pyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

Abstract: The present invention includes pyrrolopyrimidine compounds that selectively inhibit Mer tyrosine kinase (MerTK) activity and/or Tyro3 tyrosine kinase activity, and use of these pyrrolopyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

Abstract: Compounds of Formula I are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof.